ABCL AbCellera Biologics Inc.
Company Analysis
Latest News
AbCellera Announces Positive Phase 2 Clinical Trial Results for Menopause Drug ABCL635
AbCellera Biologics Inc. announced positive top-line results from the Phase 2 clinical trial of its investigational antibody, ABCL635, for treating...
🟢 Abcellera Biologics is trading 11.4% up in pre-market ahead of ABCL635 Phase 2 data release
Abcellera Biologics is trading 11.40% up now at $7.72 after announcing that Phase 2 top-line data for ABCL635 will be released before the market opens on...
🟢 Abcellera Biologics is trading 8% up today in pre-market ahead of ABCL635 Phase 2 data
Abcellera Biologics is trading 8.06% up now at $7.49 after announcing it will release top-line Phase 2 data for ABCL635. - The data will be released before...
AbCellera to Announce Phase 2 Top-Line Data for Menopause Drug ABCL635 on August 10
AbCellera Biologics announced it will release top-line results from its Phase 2 clinical trial for ABCL635, a potential first-in-class treatment for...
AbCellera's $112 Million Deal Haul Lifts Shares 10%, but Can Partnership Cash Paper Over a Shrinking Revenue Base Before the Big Drug Trial Verdict Arrives?
Shares of AbCellera Biologics surged 10.1% to $6.52 as investors looked past a bruising quarterly earnings miss and zeroed in on two headline-grabbing...
AbCellera's $112 Million Deal Haul Lifts Shares 10%, but Can Partnership Cash Paper Over a Shrinking Revenue Base Before the Big Drug Trial Verdict Arrives?
Shares of AbCellera Biologics surged 10.1% to $6.52 as investors looked past a bruising quarterly earnings miss and zeroed in on two headline-grabbing...
🟢 Abcellera Biologics is trading 8% up today in after-hours trading ahead of ABCL635 Phase 2 readout
Abcellera Biologics is trading 7.56% up now at $7.45 after the August 7, 2026 session, when shares closed at $6.93, as weak payrolls strengthened the broader...
🟢 Abcellera Biologics is trading 10.14% up today on collaboration payments and imminent ABCL635 data
Abcellera Biologics is trading 10.14% up now at $6.52 after investors focused on more than $112 million in new collaboration upfront payments and imminent...
🟢 Abcellera Biologics is trading 5% up today on ABCL635 menopause-trial data optimism
Abcellera Biologics is trading 5.07% up now at $6.22, supported by pipeline optimism despite weaker-than-expected second-quarter results. - On August 5, 2026,...
AbCellera's second quarter revenue of $4.1M misses estimates as its net loss widens to $55.4M.
AbCellera reported second quarter 2026 revenue of $4.1 million, a significant decrease from $17.1 million in the same period last year. The company posted a...
🟢 Abcellera Biologics is trading 5.1% up today ahead of Q2 earnings and clinical readout
Abcellera Biologics is trading at $6.13 (5.1% up) ahead of its Q2 2026 earnings release on August 5, with investor attention centered on upcoming clinical...
Abcellera Biologics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Abcellera Biologics to report a Q2 2026 revenue of $7.85 million and a loss per share of $0.17, with the current stock price of $5.83 trading...
🟢 Abcellera Biologics is trading 5% up today amid a broader market risk-on move
Abcellera Biologics is trading at $6.00 (+5.01%) today, moving higher in tandem with a broader market rally despite a lack of company-specific news. • The...
🟢 Abcellera Biologics is trading 5% up today after announcing a $28M Vertex collaboration
Abcellera Biologics is trading at $5.56 (5% up) after announcing a new R&D collaboration with Vertex Pharmaceuticals. • The agreement includes a $28 million...
AbCellera Announces R&D Collaboration with Vertex with $28M Upfront Payment
AbCellera Biologics Inc. has entered into a collaboration agreement with Vertex Pharmaceuticals to discover, develop, and commercialize multispecific T-cell...
AbCellera and Vertex Pen Drug Discovery Deal for Autoimmune Diseases
AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals. The partnership aims to discover and develop multispecific T-cell engagers for...
🔴 Abcellera Biologics is trading 5% down today amid a broader biotechnology selloff
Abcellera Biologics is trading at $4.99 (-5.05%) today, sliding alongside a broader biotechnology selloff despite a lack of fresh company-specific...
🔴 Abcellera Biologics is trading 5.1% down today, extending a volatile week
Abcellera Biologics is trading 5.1% down at $5.38 today with no clear catalyst, extending a volatile week that has seen several sharp moves in both...
🔴 Abcellera Biologics is trading 10.4% down
Abcellera Biologics is trading at $5.79, down 10.4% from a comparison close of $6.46 during regular trading. This is a price-action follow-up, so a separate...
🔴 Abcellera Biologics is trading 5.6% down today amid sector rotation and profit-taking
Abcellera Biologics is trading 5.6% down at $6.10 today, consolidating recent gains amid broader volatility in growth and healthcare names. • The stock's...